Committee approves 340B reporting, one-year manufacturer protections in Senate Bill 153

FRANKFORT, Ky. — The Committee on Health Services on March 14, 2025 voted to pass Senate Bill 153 as amended, adopting language from Senate Bill 14 that prohibits pharmaceutical manufacturers from discriminating against 340B covered entities and that establishes new state reporting requirements for those entities.

The substitute deleted the original provisions of SB 153 and inserted the Senate Bill 14 text, including a one-year sunset on the new manufacturer-protection provisions and a continuing reporting requirement for 340B covered entities, committee Chair Representative Kim Mosier said. "The substitute that we have before us tonight deletes all of the original provisions of the bill ... and, in its place we are adding the provisions of Senate Bill 14, which prohibits the discrimination, by a pharmaceutical manufacturer against a 340B covered entity and it will add a new section of KRS Chapter 216 to establish reporting requirements for the 340B covered entities," Mosier said.

Why it matters: supporters said the reporting will give state and federal policymakers data to assess how 340B savings are passed to communities and whether program protections are needed. Opponents and some members voiced concern that the bill could impose reporting burdens on hospitals and that the temporary protection could leave questions unresolved after the sunset.

What the bill requires and how state agencies will use the information

Under the committee substitute, eligible…